select a format

Single User License
USD 250 INR 16045
Site License
USD 500 INR 32090
Corporate User License
USD 750 INR 48135

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Valneva SE (VLA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Valneva SE (VLA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH456494D
  • |
  • Pages: 74
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Valneva SE (Valneva) is a biotechnology company that develops, manufactures and commercializes vaccines for the treatment of people with infectious diseases. The company's products include IXIARO, an encephalitis vaccine and DUKORAL, which is indicated for the prevention of cholera. It vaccines in development include candidates against clostridium difficile and lyme borreliosis. Valneva's pre-clinical programs include vaccines against zika, chikungunya, yellow-fever and human metapneumovirus diseases. The company's technologies include EB66 cell line, a proprietary embryonic stem cell-based technology which is used for the production of human and veterinary viral and therapeutic vaccines; and IC31, a synthetic vaccine adjuvant. Valneva has its facilities in Livingston, Solna and others. It has a presence in France, Austria, the UK, Sweden, the US, and Canada. Valneva is headquartered in Lyon, France.

Valneva SE (VLA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Valneva SE, Medical Devices Deals, 2011 to YTD 2017 10

Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Valneva SE, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Valneva to Secure USD18 Million from Funds Managed by Athyrium 13

BliNK Biomedical Raises Funds through Series A Venture Financing 13

Valneva Austria Raises US$30 Million In Venture Financing 14

Private Equity 15

Valneva Raises USD8 Million in First Tranche of Private Equity Investment 15

Partnerships 16

Seqirus Enters into Distribution Agreement with Valneva 16

Valneva Enters into R&D Agreement with GlaxoSmithKline 17

Valneva Enters into Distribution Agreement with PaxVax 18

PaxVax Enters into Distribution Agreement with Valneva 19

Valneva Forms Joint Venture with BliNK Therapeutics 19

Licensing Agreements 20

Bavarian Nordic Enters into Licensing Agreement with Valneva 20

Valneva Enters into Licensing Agreement with Jianshun Biosciences 21

Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 22

Valneva to Enter into Licensing Agreement with Pharma Company 23

Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 23

GeoVax Labs Enters into Licensing Agreement with Valneva 24

Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 25

Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 26

Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 27

Equity Offering 28

Valneva Raises USD54 Million in Rights Offering 28

Valneva Completes Rights Offering Of Shares For US$53.5 Million 29

Asset Transactions 31

Valneva To Sell Clinical Manufacturing Operations Facility To Biological E 31

Acquisition 32

Valneva Acquires Crucell Sweden for USD54 Million 32

Valneva SE-Key Competitors 34

Key Employees 35

Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 38

Financial Announcements 38

May 11, 2017: VALNEVA Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financial Guidance and Pipeline Outlook for 2017 38

Mar 23, 2017: VALNEVA Reports Best Financial Results in the Company's History with its First Year of Positive EBITDA in 2016 41

Feb 23, 2017: VALNEVA Reports Strong Q4 and FY 2016 Business Performance; Expects Further Growth in Sales and EBITDA, R&D Progress in 2017 46

Nov 08, 2016: Valneva Reports Strong Business Performance in First Nine Months, Company Increases Financial Guidance for Full Year 2016 49

Aug 31, 2016: Valneva Reports Strong Revenue Growth And Positive EBITDA in H12016 55

May 11, 2016: VALNEVA Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financial Guidance and Pipeline Outlook for 2016 60

Mar 21, 2016: VALNEVA Announces FY 2015 Results and Confirms Positive Trend towards Strong Revenue Growth and EBITDA Break-even in 2016 65

Product News 72

07/07/2016: VALNEVA Announces Successful Generation of a Highly-purified Zika Vaccine Candidate Using its FDA-EMA Approved Japanese Encephalitis Platform 72

Apr 10, 2017: Valneva to Present at the 17th World Vaccine Congress in Washington D.C. 73

Appendix 74

Methodology 74

About GlobalData 74

Contact Us 74

Disclaimer 74

List of Figures

Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Valneva SE, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Valneva SE, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Valneva SE, Deals By Therapy Area, 2011 to YTD 2017 9

Valneva SE, Medical Devices Deals, 2011 to YTD 2017 10

Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Valneva to Secure USD18 Million from Funds Managed by Athyrium 13

BliNK Biomedical Raises Funds through Series A Venture Financing 13

Valneva Austria Raises US$30 Million In Venture Financing 14

Valneva Raises USD8 Million in First Tranche of Private Equity Investment 15

Seqirus Enters into Distribution Agreement with Valneva 16

Valneva Enters into R&D Agreement with GlaxoSmithKline 17

Valneva Enters into Distribution Agreement with PaxVax 18

PaxVax Enters into Distribution Agreement with Valneva 19

Valneva Forms Joint Venture with BliNK Therapeutics 19

Bavarian Nordic Enters into Licensing Agreement with Valneva 20

Valneva Enters into Licensing Agreement with Jianshun Biosciences 21

Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 22

Valneva to Enter into Licensing Agreement with Pharma Company 23

Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 23

GeoVax Labs Enters into Licensing Agreement with Valneva 24

Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 25

Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 26

Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 27

Valneva Raises USD54 Million in Rights Offering 28

Valneva Completes Rights Offering Of Shares For US$53.5 Million 29

Valneva To Sell Clinical Manufacturing Operations Facility To Biological E 31

Valneva Acquires Crucell Sweden for USD54 Million 32

Valneva SE, Key Competitors 34

Valneva SE, Key Employees 35

Valneva SE, Other Locations 36

Valneva SE, Subsidiaries 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Valneva SE, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com